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Malignant rhabdoid tumor was originally described in the kid-
ney as a variant of Wilms' tumor in 1978 by Beckwith and Palmer
[1]. Extrarenal forms of this tumor are very rare but have been
described in a variety of sites including soft tissues, paraspinal and
paratesticular areas, the central nervous system, colon, tongue,
prostate, liver, skin, thymus, heart, pelvis, uterus, and vulva. Only 13
vulvar cases have been reported thus far in the English literature.
We are reporting the 14th case and a review of the clinical features,
management and prognosis of all cases.
A 51-year-old G4P3, postmenopausal woman presented to our
Obstetrics and Gynecology Clinic, Erciyes University Faculty of
Medicine, Kayseri, Turkey with a painless vulvar mass measuring
3 cm that was situated on the left labium major adjacent to the
anterior comissura. The lesion ﬁrst appeared 2 months previously
and was locally excised by a gynecologist at a secondary care center
with the presumed diagnosis of lipoma. The histopathological ex-
amination revealed an extrarenal rhabdoid tumor (ERT). At the
time of referral to our center, 20 days after the excision, a recurrent
tumor measuring 4 cm, which was painless, with irregular border
and arising from the excision site was detected (Figure 1). On
transvaginal ultrasonography, the uterus, endometrial thickness,
and both ovaries were normal. A positron emission tomography/
computer tomography with 18-F-ﬂudeoxyglucose (18-F-FDG
PET/CT) was performed for metastases screening. The 18-F-FDG
PET/CT detected a soft-tissue lesion showing hypermetabolic* Corresponding author. Department of Obstetrics and Gynecology, Erciyes Uni-
versity, Faculty of Medicine, Gevher Nesibe Hospital, Talas Street 5.km, 38039,
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).activity at the left labium major, measuring 39 mm  37 mm with
irregular borders. The 18-F-FDG PET/CT image showed no lesion
suspicious for metastasis. A wide local excision was performed with
1 cm surgical margin and pathologic examination conﬁrmed ERT
with negative margins.
Microscopically, tumor cells make a row of diffuse layers and
prominent pleomorphism and atypia are remarkable. The tumor
was composed of large polygonal cells, with extended basophilic
cytoplasm. Nuclei were vesicular with distinctive nucleolus.
Immunohistochemically, the neoplastic cells were diffusely posi-
tive for vimentin, CD 99, and Fli-1 and focally positive for panker-
atin and epithelial membrane antigen. However, neoplastic cells
were negative for cytokeratin 5/6, P63, human melanoma black
monoclonal antibody 45, CD 34, desmin, S-100, actin, melan A,
myoglobin, Wilms tumor-1, neuron-speciﬁc enolase, and syn-
aptaophycin, which was consistent with the diagnosis of high-
grade malignant rhabdoid tumor (Figure 2).
On complete healing of the operative wound, she was referred
to the Radiation Oncology Department, Erciyes University Faculty
of Medicine for adjuvant radiotherapy in view of aggressive his-
tology, grade, and size (> 3 cm). Shewas treatedwith external beam
radiotherapy of 60 Gy over a period of 4 weeks (5 d/wk) to prevent
local recurrence. At 12 months from her initial diagnosis, she is
alive without evidence of recurrent or metastatic disease.
Vulvar carcinoma is a very rare neoplasm that accounts for
about 4% of all gynecological cancers and typically affects women
in the 6th decade and 7th decade of their lives. The vast majority of
vulvar cancers (~90%) are squamous cell carcinoma. Other cell
types that are found less frequently are malignant melanoma,
anaplastic carcinomas, adenocarcinoma of the Bartholin glands,
and sarcomas [2].
ERT of the vulva is a rare but very aggressive neoplasm. Only 13
cases have been reported thus far in the English literature and six of
those reported to date, died within a year of diagnosis (Table 1).
The majority of reported cases of ERTs of the vulva had a history
of rapidly growing, painless mass on the labium major (8 of 13
cases: 3 right, 5 left). Other reported sites are the vulva (2 cases: 1
right, 1 left), clitoris (1 case), mons pubis (1 case), and one case at
the mons pubis adjacent to the labium major as in our case. Inby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
Figure 1. Painless, irregularly bordered recurrent tumor arising from the excision site.
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ported ERT cases were noted in young patients. The mean age of
ERT patients was 38.5 ± 12.1 years (range, 19e63 years; Table 1).
The diagnosis of ERT is based on histopathology. Pathological
evaluationwith light microscopy and immunohistochemistry is the
gold standard for differential diagnosis. It is important and difﬁcult
to differentiate ERT from epitheloid sarcoma, which is a rare soft
tissue malignancy of mesenchymal origin, because of nonstandard
immunohistologic criteria [3]. Broadly, these tumors express EMA,
vimentin, and cytokeratins. They do not express desmin [4].
Exclusion of malign melanoma can be done with positive S100 and
HMB stains, which should be negative in ERT. Additionally, it is
useful to perform dysadherin expression assay, positive in epi-
theloid tumors, to differentiate ERT and epitheloid tumors [5].
There is no consensus on the treatment of vulvar ERT. Because of
the aggressive pattern and tendency for the early metastasis of
these tumors, it may be useful to make PET-CT before treatment.
However, the role of PET-CT in themanagement of these cases is yet
to be determined. A radical resection either alone or in combination
with inguinal lymph node dissection has been performed inmost of
the reported cases (9 cases with lymph node dissection, 4 cases
local excision, and 1 case unknown). Although most of the cases
were treated with local excision plus lymph node dissection, the
accuracy of this process is unclear because of the negative histologyFigure 2. (A) Malignant extrarenal rhabdoid tumor composed of sheets of large epithelioid
macronucleoli (hematoxylin and eosin, 200). (B) Diffuse cytoplasmic immunoreactivity foof these nodes [6]. It is well known that vulvar sarcomas, unlike
carcinomas, rarely spread via the lymphatic route. Because of this,
lymph node dissection may lead to additional morbidity and delay
in starting adjuvant therapy. Nevertheless, Chen et al [7] reported a
case of ERT with lymphatic involvement. Sentinel lymph node
detection, which is a less invasive method for evaluating lymphatic
involvement, may be a good alternative in these cases. Perrone et al
[8] and Brand et al [3] performed only surgery with or without
lymph node dissection in four cases and all of them recurred
rapidly. In two cases reported by Matias et al [9] and Igarashi et al
[10], initially local excision and adjuvant chemotherapy were per-
formed. One of them died 9 months after diagnosis and the other
was alive 8 months after the initial treatment [9,10]. Two of 13
patients were treated with surgery plus chemoradiotherapy. After
4 months, one of them died with mediastinal and lymphatic me-
tastases. The other patient died 8 months after initial treatment
with lung metastases. Chen et al [7] performed surgery plus a
combination of metronomic chemotherapy with paclitaxel and the
antiangiogenic agent thalidomide. They recommended pel-
viceinguinal radiotherapy but the patient refused [7]. Together
with the present case, four patients were treated with surgery plus
radiotherapy and no recurrence was detected.
The role of adjuvant chemotherapy and radiotherapy after local
excision is controversial in the treatment of ERT. Adjuvant
chemotherapy has been used in ﬁve of the 13 patients and four of
these ﬁve patients died within months. Gururangan et al [11] used
multiple-agent chemotherapy in extracranial rhabdoid tumors and
reported partial response. Ulutin et al [12] recommended post-
operative adjuvant radiotherapy for patients with close surgical
margins, with residual tumor, or with high-grade tumors. Together
with our patient, six of all the cases previously reported have been
treated with adjuvant radiotherapy. Because of aggressive histol-
ogy, high grade, and gross tumor size, we preferred to combine
surgery with adjuvant radiotherapy for local control. However,
early local recurrence has been reported in a case with ERT despite
combined surgery plus adjuvant radiotherapy [13].
The reported median survival for patients with ERT is relatively
short. Six of the 13 patients treated as ERTof the vulva died within a
year of diagnosis. One of the Perrone et al's [8] patients died
138 months after diagnosis. Given the paucity of data, accurate
estimation of survival in these patients is difﬁcult, and larger series
need to be reported.
In summary, ERTof the vulva is a very rare and aggressive tumor.
Wide local excision of the primary and recurrent tumor is the
treatment of choice. Adjuvant radiotherapy and chemotherapy do
not appear to be effective in treating local and metastatic tumor. To
determine a standard and effective treatment for ERT, we need
larger series to accumulate data. Therefore, clinicians are recom-
mended to present their individual cases for the establishment of
guidelines for the treatment of ERT.cells with abundant eosinophilic cytoplasm. The tumor cells have eccentric nuclei with
r vimentin in rhabdoid cells (vimentin, 40).
Table 1
Extrarenal rhabdoid tumor of the vulva: reported cases.
Study Age (y) Site Primary treatment ILND Recurrence Reported survival (mo),
status
Perrone et al 1989
(3 cases) [8]
19, 30,
31
R LM
R LM
L vulva
Surgery
þ

þ
LR
LR
LR þ lung
38, alive
8, dead
138, dead
Matias et al 1990 [9] 49 L LM Surgery þ chemotherapy  LR þ metastasis 9, dead
Lupi et al 1996 [14] 39 L LM Surgery þ chemotherapy þ radiotherapy þ Lymphatic nodes þ mediastinum
metastasis
4, dead
Igarashi et al 1998 [10] 39 L LM Surgery þ chemotherapy  No recurrence 8, alive
Sert et al 1999 [13] 44 R LM Surgery þ chemotherapy þ radiotherapy þ LR þ lung 8, dead
Brand et al 2001 [3] 40 Mons pubis Surgery þ LR 61, alive
Haidopoulos et al
2002 [15],a
? Clitoris ? ? ? ?
Tzilinis et al 2002 [16] 63 L LM Surgery þ radiotherapy þ No recurrence 30, alive
Argenta et al 2007 [4] 35 R vulva Surgery þ radiotherapy þ No recurrence 40, alive
Chen et al 2009 [7] 23 L LM Surgery þ chemotherapy þ Lymphatic nodes þ lung 7, dead
Narendra et al 2010 [6] 50 R LM þ mons
pubis
Surgery þ radiotherapy þ No recurrence 30, alive
Current case 51 L LM þ mons
pubis
Surgery þ radiotherapy  No recurrence 12, alive
ILND ¼ inguinal lymph node dissection; L ¼ left; LM ¼ labium major; LR ¼ local recurrence; R ¼ right.
a Only abstract is available.
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